Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 8/20 | 0.51 |
| ▸ | CA12 | O43570 | 7/20 | 0.51 |
| ▸ | CA2 | P00918 | 7/20 | 0.51 |
| ▸ | CA1 | P00915 | 6/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14022962 | 1.00 | CA9 (0.51) | CA9CA12CA2CA1TSHR | |
| SCHEMBL8432075 | 1.00 | CA9 (0.51) | CA9CA12CA2CA1TSHR | |
| SCHEMBL12975857 | 1.00 | CA9 (0.51) | CA9CA12CA2CA1TSHR | |
| SCHEMBL23563178 | 1.00 | CA9 (0.51) | CA9CA12CA2CA1TSHR | |
| SCHEMBL15596615 | 1.00 | CA9 (0.51) | CA9CA12CA2CA1TSHR | |
| SCHEMBL23133262 | 1.00 | CA9 (0.51) | CA9CA12CA2CA1TSHR | |
| SCHEMBL18814012 | 1.00 | CA9 (0.51) | CA9CA12CA2CA1TSHR | |
| SCHEMBL4409830 | 1.00 | CA9 (0.51) | CA9CA12CA2CA1TSHR | |
| SCHEMBL13697192 | 1.00 | CA9 (0.51) | CA9CA12CA2CA1TSHR | |
| SCHEMBL14268499 | 1.00 | CA9 (0.51) | CA9CA12CA2CA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052134-B1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3280450-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | Merck Sharp & Dohme Corp. (US) | 2018-02-14 | — | — | EP | disclosed |
| US-9889205-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9884125-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2016164288-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-09-01 | — | — | US | disclosed |
| US-9427475-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2016-08-30 | — | — | US | disclosed |
| EP-3052134-A2 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | Merck Sharp & Dohme Corp. (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME LLC | 2015-04-16 | — | — | US | disclosed |
| WO-2015051052-A2 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | CA9 2526/4885CA12 1075/4885CA2 4534/4885 |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | CA9 2512/4885CA12 1044/4885CA2 4528/4885 |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | CA9 2736/4885CA12 1084/4885CA2 4612/4885 |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | CA9 2512/4885CA12 1044/4885CA2 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.